Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial
Authors:
- 6 November 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 158 (1) , 116-121
Abstract
Background When this study was initiated, no previous studies comparing methotrexate and ciclosporin for moderate to severe plaque psoriasis had been performed. Objectives To compare the effectiveness, quality of life and side-effects of methotrexate and ciclosporin treatments in a context reflecting normal clinical practice. Methods Eighty-four patients with moderate to severe plaque psoriasis were randomized to treatment with methotrexate or ciclosporin for 12 weeks. The primary outcome was the Psoriasis Area and Severity Index (PASI). The secondary outcome was quality of life, measured by the Dermatology Life Quality Index (DLQI) and the 36-item Short Form Health Survey (SF-36). A visual analogue scale (VAS) was used for patients' assessment. Results Sixty-eight patients started treatment and were included in the analysis. Dropout before initiation of treatment was higher in the ciclosporin group. Mean PASI change from baseline at 12 weeks was 58% in the methotrexate group and 72% in the ciclosporin group, showing ciclosporin to be more effective than methotrexate. Improvement of the VAS score was higher in the ciclosporin group. The methotrexate group showed a greater improvement in the subscale Physical Functioning of the SF-36. No significant difference between the groups was found for DLQI. Conclusions Treatment with methotrexate or ciclosporin for chronic plaque psoriasis brings satisfactory disease control, improved quality of life and tolerable side-effects. A statistically significant difference in effectiveness between treatment groups was recorded, showing ciclosporin to be more effective than methotrexate in a short-term perspectiveKeywords
This publication has 22 references indexed in Scilit:
- Methotrexate for psoriasis: current European practice. A postal surveyJournal of the European Academy of Dermatology and Venereology, 2005
- Methotrexate versus Cyclosporine in Moderate-to-Severe Chronic Plaque PsoriasisNew England Journal of Medicine, 2003
- Efficacy and Safety of Cyclosporine versus Methotrexate in Severe Psoriasis: A Study from North IndiaThe Journal of Dermatology, 2003
- Risk of Malignancies in Psoriasis Patients Treated with Cyclosporine: a 5 y Cohort StudyJournal of Investigative Dermatology, 2003
- How Genetic Defects Are IdentifiedClinics in Dermatology, 1998
- A systematic review of five systemic treatments for severe psoriasisBritish Journal of Dermatology, 1997
- Mechanisms of Cyclosporine A Inhibition of Antigen-Presenting Activity in Uninvolved and Lesional Psoriatic EpidermisJournal of Investigative Dermatology, 1990
- CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines.Proceedings of the National Academy of Sciences, 1989
- Cyclosporine improves psoriasis in a double-blind studyJAMA, 1986
- Treatment of Psoriasis with Folic Acid AntagonistsArchives of Dermatology, 1958